Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis

References

• Bouchard J, Ghannoum M, Bernier-Jean A, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol. 2015;53:156–163.
   PubMed Web of Science ®Google Scholar
• Thibault N, Morrill AM, Willett KC. Idarucizumab for reversing dabigatran-induced anticoagulation: a systematic review. Am J Ther. 2018;25:e333–e338.
   PubMed Web of Science ®Google Scholar
• Simon A, Domanovits H, Ay C, et al. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost. 2017;15:1317–1321.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Australian product information: Praxbind. 2016.
   Google Scholar
• Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431–441.
   PubMed Web of Science ®Google Scholar
• Sié P. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Des Devel Ther. 2016;10:1683–1689.
   PubMed Web of Science ®Google Scholar
• Marino KK, Santiago RA, Dew RB 3rd, et al. Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis. Pharmacotherapy 2016;36:e160–e165.
   PubMed Web of Science ®Google Scholar
• Thorborg C, Horn E-P, Mofid H, et al. Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus. Br J Anaesth. 2016;117:407–409.
   PubMed Web of Science ®Google Scholar
• Alhashem HM, Avendano C, Hayes BD, et al. Persistent life-threatening hemorrhage after administration of idarucizumab. Am J Emerg Med. 2017;35:193.
   PubMed Web of Science ®Google Scholar
• Henderson RSJ, Deshpande S, Williams B, et al. Idarucizumab for dabigatran reversal in emergency type-A aortic dissection. J Cardiothorac Vasc Anesth. 2017;31:e80–e81.
   PubMedGoogle Scholar
• Steele AP, Lee JA, Dager WE. Incomplete dabigatran reversal with idarucizumab. Clin Toxicol. 2018;56:216–218.
   PubMed Web of Science ®Google Scholar
• Goriacko P, Yaghdjian V, Koleilat I, et al. The use of idarucizumab for dabigatran reversal in clinical practice: a case series. PT. 2017;42:699–703.
   PubMedGoogle Scholar
• Mazur P, Darocha T, Filip G, et al. Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Polish Arch Intern Med. 2016;126:579–581.
   Google Scholar
• Peetermans M, Pollack C Jr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol. 2016;54:644–646.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Bhatnagar N, Khan A, et al. Idarucizumab for dabigatran overdose in a child. Br J Haematol. 2018;180:457–459.
   PubMed Web of Science ®Google Scholar
• Fang C-W, Tsai YT, Chou PC, et al. Intravenous thrombolysis in acute ischemic stroke after idarucizumab reversal of dabigatran effect: analysis of the cases from Taiwan. J Stroke Cerebrovasc Dis. 2019;28:815–820.
   PubMed Web of Science ®Google Scholar
• Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - a national case collection. Int J Stroke 2017;12:383–391.
   PubMed Web of Science ®Google Scholar
• Tse DM, Young L, Ranta A, et al. Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. J Neurol Neurosurg Psychiatry 2018;89:549–550.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol. 2014;63:321–328.
   PubMed Web of Science ®Google Scholar
• Chin PKL, Vella‐Brincat JWA, Barclay ML, et al. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol. 2012;74:734–740.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48:1411–1419.
   PubMed Web of Science ®Google Scholar
• Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554–3562.
   PubMed Web of Science ®Google Scholar
• Sarah S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol. 2013;53:1–13.
   PubMed Web of Science ®Google Scholar
• Reilly PA, van Ryn J, Grottke O, et al. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Emerg Med. 2016;34:26–32.
   PubMed Web of Science ®Google Scholar
• Reilly PA, van Ryn J, Grottke O, et al. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. 2016;129:S64–S72.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Van Ryn J, et al. Idarucizumab the antidote for reversal of dabigatran. Circulation 2015;132:2412–2422.
   PubMed Web of Science ®Google Scholar
• Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care 2016;24:6–46.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Australian Product Information: Pradaxa. 2008.
   Google Scholar
• Glund S, Stangier J, van Ryn J, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet. 2017;56:41–54.
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Adminisration. Australian public assessment report for idarucizumab. 2016.
   Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49:259–268.
   PubMed Web of Science ®Google Scholar
• Glund S, Gan G, Moschetti V, et al. The renal elimination pathways of the dabigatran reversal agent idarucizumab and its impact on dabigatran elimination. Clin Appl Thromb Hemost. 2018;24:724–733.
   PubMed Web of Science ®Google Scholar
• Yip L, Deng J‐F. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment. J Thromb Haemost. 2017;15:2466–2467.
   PubMedGoogle Scholar
• Yip L, Deng J-F. Idarucizumab dosing in kidney failure. Am J Kidney Dis. 2018;71:146.
   PubMed Web of Science ®Google Scholar
• Quintard H, Viard D, Drici MD, et al. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. Thromb Haemost. 2017;117:196–197.
   PubMed Web of Science ®Google Scholar
• Rottenstreich A, Jahshan N, Avraham L, et al. Idarucizumab for dabigatran reversal - does one dose fit all? Thromb Res. 2016;146:103–104.
   PubMed Web of Science ®Google Scholar
• Yasaka M, Ikushima I, Harada A, et al. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Res Pract Thromb Haemost. 2017;1:202–215.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet. 2007;46:897–939.
   PubMed Web of Science ®Google Scholar
• Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386:680–690.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Yip L, Deng JF. Idarucizumab dosing in patients with excessive dabigatran body burden. Br J Anaesth. 2019;122:e20–e22.
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen J-M, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Center for Drug Evaluation and Research. Application Number: 761025Orig1s000. Clinical Pharmacology and Biopharmaceutics Review. 2015.
   Google Scholar
• Macey RI, Oster GF, Zahnley T. Berkeley Madonna user’s guide. University of California, Berkeley, CA, 2009. http://www.berkeleymadonna.com/.
   Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–295.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Sevastos J, Carland JE, et al. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. CJASN. 2018;13:1254–1263.
   PubMed Web of Science ®Google Scholar
• Vosko MR, Bocksrucker C, Drwiła R, et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis 2017;43:306–317.
   PubMed Web of Science ®Google Scholar
• Tomaszuk-Kazberuk A, Łopatowska P, Młodawska E, et al. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm. Polish Arch Intern Med. 2017;127:68–70.
   PubMedGoogle Scholar
• Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Raco V, Ahuja T, Green D. Assessment of patients post reversal with idarucizumab. J Thromb Thrombolysis 2018;46:466–472.
   PubMed Web of Science ®Google Scholar
• von Wowern F, Brizzi M, Holst J. Reversal of the anticoagulation effects of dabigatran etexilate by idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke. Eur J Case Reports Intern Med. 2017;4:4.
   Google Scholar
• Agosti S, Casalini L, Daffonchio A, et al. Emergency lumbar puncture for suspected meningitis after dabigatran reversal with idarucizumab: a case report. J Clin Case Rep. 2018;08:1103.
   Google Scholar
• Billoir P, Girault C, Barbay V, et al. Management of dabigatran after overdosage: two case reports and suggestions for monitoring. Blood Coagul Fibrinolysis 2018;29:653–655.
   PubMed Web of Science ®Google Scholar
• Comuth WJ, Haase AM, Henriksen LØ, et al. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis. Scand J Clin Lab Invest. 2018;78:1–5.
   PubMed Web of Science ®Google Scholar
• Novak JE, Alamiri K, Yee J. Dabigatran reversal in a patient with end-stage liver disease and acute kidney injury. Am J Kidney Dis. 2017;71:137–141.
   PubMed Web of Science ®Google Scholar
• Tsai YT, Hsiao YJ, Tsai LK, et al. Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: two cases with hemorrhagic transformation. J Neurol Sci. 2018;388:155–157.
   PubMed Web of Science ®Google Scholar
• Gendron N, Gay J, Lemoine M, et al. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. Haematologica 2018;103:e226–e229.
   PubMed Web of Science ®Google Scholar
• Giannandrea D, Caponi C, Mengoni A, et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry 2019;90:619–623.
   PubMed Web of Science ®Google Scholar
• Pretnar Oblak J, Sabovic M, Frol S. Intravenous thrombolysis after idarucizumab application in acute stroke patients—a potentially increased sensitivity of thrombi to lysis? J Stroke Cerebrovasc Dis. 2019;28:768–773.
   PubMed Web of Science ®Google Scholar
• Brennan Y, Favaloro EJ, Pasalic L, et al. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Intern Med J. 2019;49(1):59–65.
   PubMed Web of Science ®Google Scholar
• Dager WE, Roberts AJ, Nishijima DK. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thromb Res. 2019;173:71–76.
   PubMed Web of Science ®Google Scholar
• Elalamy I, Crisan O, Gruenenfelder F, et al. Early-access programme in emergency care: idarucizumab use for rapid dabigatran reversal in critical care patients. Eur J Emerg Med. 2019;26:230–231.
   PubMed Web of Science ®Google Scholar
• Kalmanovich E, Gaudard P, Roubille F. Letter on ‘Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. Eur J Heart Fail. 2018;21:818.
   Web of Science ®Google Scholar
• Küpper C, Feil K, Klein M, et al. Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa® in clinical routine (MR REPAIR). J Neurol. 2019;266:2807–2811.
   PubMed Web of Science ®Google Scholar
• Oberladstätter D, Voelckel W, Bruckbauer M, et al. Idarucizumab in major trauma patients: a single centre real life experience. Eur J Trauma Emerg Surg. 2019.
   Google Scholar
• Šaňák D, Jakubíček S, Černík D, et al. Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience. J Stroke Cerebrovasc Dis. 2018;27:2479–2483.
   PubMed Web of Science ®Google Scholar
• van der Wall SJ, van Rein N, van den Bemt B, et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Eurospace 2019;21:414–420.
   Google Scholar
• Wheeler M, Borrie A, Dookia R, et al. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre. Intern Med J. 2019;49:1316–1320.
   PubMed Web of Science ®Google Scholar
• George S, Taburyanskaya M, Lewis V. Probable drug–drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. Blood Coagul Fibrinolysis 2019;30:42–46.
   PubMed Web of Science ®Google Scholar
• Mcbride L, Wang J, Ho P, et al. Dabigatran toxicity in acute kidney injury: hemodialysis and idarucizumab required. Kidney Int Rep. 2019;4:500–504.
   PubMed Web of Science ®Google Scholar
• Sheikh-Taha M. Idarucizumab for reversal of dabigatran: single-center real-world experience. Am J Cardiovasc Drugs 2019;19:59–64.
   PubMed Web of Science ®Google Scholar
• Hajsmanova Z, Sigutova P, Lavickova A. Repeated administration of idarucizumab to a patient with dabigatran overdose. Hamostaseologie 2018;38:39–42.
   PubMed Web of Science ®Google Scholar
• Gendron N, Flament H, Litvinova E, et al. The (fab)ulous destiny of idarucizumab: highlighting its interference with urine protein immunofixation. TH Open 2019;3:e306–e308.
   PubMedGoogle Scholar
• Sheikh-Taha M. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury. Am Soc Heal Pharm. 2019;76:9–12.
   PubMed Web of Science ®Google Scholar
• Hegemann I, Ganter C, Widmer CC, et al. Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab. Br J Anaesth. 2018;121:505–508.
   PubMed Web of Science ®Google Scholar
• Fanikos J, Murwin D, Gruenenfelder F, et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO Surveillance Program. Thromb Haemost. 2020;120(1):27–35.
   PubMed Web of Science ®Google Scholar
• Sowerby LJ, Vella-Brincat J. Three-month use of idarucizumab at Christchurch hospital through the emergency department and MedChartTM. N Z Med J. 2019;132(1499):18–22.
   PubMed Web of Science ®Google Scholar
• Gendron N, Feral-Pierssens AL, Jurcisin I, et al. Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clin Case Rep. 2017;5:346–350.
   PubMed Web of Science ®Google Scholar
• Jala S, O’brien E. Treatment with intravenous alteplase for acute ischemic stroke after reversal of dabigatran with idarucizumab: a case study. J Neurosci Nurs. 2019;51:21–25.
   PubMed Web of Science ®Google Scholar
• Sauter TC, Blum S, Nagler M, et al. Reversal of dabigatran using idarucizumab in a septic patient with impaired kidney function in real-life practice (case report). Case Rep Emerg Med. 2016;2016:1393057.
   Google Scholar
• Stecher A, Vene N, Mavri A, et al. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure. Eur J Anaesthesiol. 2017;34:400–402.
   PubMed Web of Science ®Google Scholar
• Novak JE, Alamiri K, Yee J. In reply to ‘Idarucizumab dosing in kidney failure’. Am J Kidney Dis. 2018;71:146–147.
   PubMed Web of Science ®Google Scholar
• Humphries K, Huggan P, Stiles M, et al. Life-threatening bleeding due to persistent dabigatran effect in a patient with sepsis despite idarucizumab therapy and haemodialysis. BMJ Case Rep. 2019;12:e230125.
   PubMedGoogle Scholar
• Shiroshita A, Nakashima K, Tanaka Y, et al. Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report. J Thromb Thrombolysis 2018;46:271–273.
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–399.
   PubMed Web of Science ®Google Scholar
• Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical pharmacokinetics in kidney disease. CJASN. 2018;13:1085–1095.
   PubMed Web of Science ®Google Scholar
• Awesat J, Sagy I, Haviv YS, et al. Dabigatran-induced nephropathy and its successful treatment with Idarucizumab – case report and literature review. Thromb Res. 2018;169:120–122.
   PubMed Web of Science ®Google Scholar
• Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013;52:243–254.
   PubMed Web of Science ®Google Scholar
• Harrison MF. The misunderstood coagulopathy of liver disease: a review for the acute setting. WestJEM 2018;19:863–871.
   Google Scholar
• Avecilla ST, Ferrell C, Chandler WL, et al. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137:572–574.
   PubMed Web of Science ®Google Scholar
• Blommel ML, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Heal Pharm. 2011;68:1506–1519.
   PubMed Web of Science ®Google Scholar
• Safouris A, Triantafyllou N, Parissis J, et al. The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio. Ther Adv Neurol Disord. 2015;8:245–254.
   PubMed Web of Science ®Google Scholar
• Sotomi Y, Hirata A, Amiya R, et al. Bleeding risk of add-on anti-platelet agents to direct oral anticoagulants in patients with nonvalvular atrial fibrillation (from 2216 patients in the DIRECT Registry). Am J Cardiol. 2019;123:1293–1300.
   PubMed Web of Science ®Google Scholar
• Franchini M, Bonfanti C, Mannucci PM. Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost. 2015;41:788–801.
   PubMed Web of Science ®Google Scholar
• Crapelli GB, Bianchi P, Isgro G, et al. A case of fatal bleeding following emergency surgery on an ascending aorta intramural hematoma in a patient taking dabigatran. J Cardiothorac Vasc Anesth. 2016;30:1027–1031.
   PubMed Web of Science ®Google Scholar
• Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138–143.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127.
   PubMed Web of Science ®Google Scholar
• Dager WE, Gosselin RC, Kitchen S, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627–1636.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–378.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.
   PubMed Web of Science ®Google Scholar
• Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493–1502.
   PubMed Web of Science ®Google Scholar
• Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost. 2016;14:2194–2201.
   PubMed Web of Science ®Google Scholar
• Tran H, Joseph J, Young L, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44:525–536.
   PubMed Web of Science ®Google Scholar
• Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623–627.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Idarucizumab for reversing anticoagulation in adults treated with dabigatran: a review of the clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jan 31. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442166/.
   Google Scholar
• Glund S, Stangier J, van Ryn J, et al. Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol. 2016;67:1654–1656.
   PubMed Web of Science ®Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15:09S–16S.
   PubMed Web of Science ®Google Scholar